Cryosurgical Ablation (CSA) — Precision Cold Therapy for Solid Tumors
Overview
Cryosurgical Ablation (CSA) is a clinically proven, minimally invasive tumor ablation technique that uses extreme cold to destroy cancer cells with precision. First approved by the U.S. FDA in 1998 and subsequently by regulatory authorities in China and other countries, CSA has since been applied to thousands of patients worldwide across more than 30 different tumor types. At BIOOCUS Medical Group, we coordinate access to expert CSA centers in China, connecting international patients with experienced oncology teams who have performed this procedure on a large scale.
How It Works
CSA is based on a controlled freeze-thaw cycle that selectively destroys tumor tissue. Under ultrasound or CT imaging guidance, a cryoprobe (approximately 1.4–2 mm in diameter) is inserted percutaneously into the tumor. Argon gas is then delivered through the probe, rapidly cooling the target tissue to temperatures as low as −160°C to −170°C within 15 seconds, forming a precisely shaped ice ball that engulfs the tumor and a 5–10 mm safety margin of surrounding tissue.
After 15–20 minutes of sustained freezing, helium gas is introduced to rapidly rewarm the frozen tissue from −140°C back to approximately +20°C to +40°C. This freeze-rewarming cycle is repeated at least twice per session to maximize cell destruction. The full process is monitored in real time by ultrasound or CT imaging, with computer-controlled precision over temperature, timing, and ice ball geometry.
The mechanisms of tumor destruction are multi-layered:
- Rapid freezing causes intracellular ice crystal formation, resulting in direct cell membrane rupture and dehydration.
- Microvascular damage within the tumor leads to ischemia and secondary cell death.
- Necrotic tumor tissue remaining in situ acts as an antigen, stimulating a systemic anti-tumor immune response (the "abscopal effect").
- Post-ablation, residual cancer cells show heightened sensitivity to chemotherapy and radiotherapy, enabling synergistic combination treatment strategies.
Key Advantages
- Minimally Invasive with Rapid RecoveryThe cryoprobe's small diameter and percutaneous approach minimize surgical trauma. Patients typically experience less blood loss, shorter procedure times, and faster post-operative recovery compared to open surgery. The procedure can be repeated if necessary.
- Applicable to a Wide Range of Tumor Types and SizesUnlike thermal ablation techniques, CSA is effective for both small tumors and large tumors exceeding 5 cm in diameter, as well as multiple simultaneous lesions. Multiple probes can be deployed concurrently to cover larger ablation zones.
- Safe Near Critical StructuresThe blood flow within large vessels provides a natural heat-releasing effect, reducing the risk of vascular injury during cryoablation. This makes CSA suitable for tumors located adjacent to major blood vessels that would otherwise be inoperable.
- Real-Time Imaging GuidanceThe expanding ice ball is clearly visualized under ultrasound or CT throughout the procedure, allowing physicians to confirm complete tumor coverage and immediately identify any residual untreated tissue for repeat ablation.
- No Systemic ToxicityCSA is a physical ablation technique. It does not produce the systemic toxicities associated with chemotherapy or radiation therapy, making it a well-tolerated option for patients with compromised performance status or those who have exhausted other systemic treatment lines.
- Immune ActivationCryoablation-induced tumor cell death triggers the release of tumor antigens in situ, which can prime the immune system against both local and distant (metastatic) disease. This immunostimulatory property makes CSA a compelling partner for immunotherapy approaches such as CAR-T therapy and checkpoint inhibitors.
- Synergistic with Chemotherapy and RadiationFollowing ablation, residual tumor cells demonstrate increased sensitivity to chemotherapy and radiotherapy. Palliative CSA can reduce the doses and duration of subsequent systemic treatments, thereby lowering the risk of treatment-related complications.
Indications
CSA is applicable to virtually all solid tumors, including but not limited to:
Liver cancer · Lung cancer · Kidney cancer · Pancreatic cancer · Breast cancer · Prostate cancer · Ovarian cancer · Bone and soft tissue tumors · Head and neck tumors · Melanoma · Uterine tumors · Cervical and vaginal cancers · Testicular cancer · Laryngeal cancer
It is particularly valuable for patients who are not candidates for surgical resection, patients with locally advanced disease adjacent to major vessels or critical structures, and patients seeking a minimally invasive option as part of a multimodal treatment plan.
Integration with Cellular Immunotherapy
At BIOOCUS Medical Group, our clinical coordinators work with oncologists to design individualized combination strategies. For selected patients, CSA can serve as a cytoreductive bridge prior to CAR-T therapy or TILs therapy, reducing tumor burden and potentially enhancing the anti-tumor immune environment to optimize the outcome of subsequent cellular immunotherapy.
Why Choose BIOOCUS for CSA Coordination
BIOOCUS connects international patients with China's leading oncology centers, which collectively hold among the highest case volumes of cryosurgical ablation in the world. Our medical coordination team provides end-to-end support, from pre-treatment evaluation and document review to in-hospital care coordination and post-treatment follow-up. Consultations are available in multiple languages.
Contact us today to request a free medical evaluation and find out whether Cryosurgical Ablation is appropriate for your case.
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.